Quest Diagnostics (DGX) Tops Q2 EPS by 210c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $4.96, $2.10 better than the analyst estimate of $2.86. Revenue for the quarter came in at $2.55 billion versus the consensus estimate of $2.38 billion.
GUIDANCE:
Quest Diagnostics sees FY2021 EPS of $10.65-$11.35, versus the consensus of $11.13. Quest Diagnostics sees FY2021 revenue of $9.54-9.79 billion, versus the consensus of $9.45 billion.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
